ArticlePloS one2025
Influence of capping agents on physicochemical properties and leukemic cytotoxicity of copper oxide nanoparticles biosynthesized using Caesalpinia sappan extract.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the effects of capping agents on the physicochemical and biological properties, particularly their leukemic cytotoxicity, of copper oxide nanoparticles (CuONPs) using a Caesalpinia sappan extract as a reducing agent. Gelatin, polyethylene glycol 400 (PEG), polysorbate 80 (P80), octyl phenol ethoxylate, sodium lauryl ether sulfate and mannitol were added as capping agents to ensure colloidal stability of the formed CuONPs. As a control, CuONPs were also synthesized using gelatin and sodium borohydride as the capping and reducing agent, respectively. The physicochemical properties of the obtained CuONPs were determined using dynamic light scattering, zeta-potential measurements, energy dispersive X-ray spectroscopy, and Fourier-transform infrared spectroscopy. Their cytotoxic effects were investigated using normal human peripheral blood mononuclear cells (PBMC) and three strains of leukemic cell lines (KG1a, K562, and Molt4). The obtained CuONPs had a size range from 175-280 nm, with a reasonable size distribution between 0.2 and 0.4 and a negative zeta potential (range -30 to -35 mV) except the particles prepared using gelatin as a stabilizer which had a zeta potential of -3 mV. The CuONPs were incubated with both healthy PBMC and three types of leukemic cells to determine their IC50 values. The IC50 values of PEG-CuONPs and P80-CuONPs against healthy PBMC were 72.5 ± 5.8 and 85.0 ± 3.1 µg/mL, respectively, while that against the three strains of leukemic cells were in the range of 26-29 and 28-41 µg/mL, respectively. The results clearly demonstrate that the biosynthesized CuONPs using PEG and P80 as a capping agent exhibited the highest selectivity index defined as IC50 of the particles for PBMC/IC50 for leukemic cells. Therefore, these CuONPs are promising candidates for preclinical in vivo for leukemic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.